1743-Ferguson, Michael
Faculty

Michael J. Ferguson, MD

Assistant Professor of Clinical Pediatrics

Bio

Dr. Michael Ferguson is an Assistant Professor of Pediatrics and Medical Director of the Pediatric Cancer Precision Genomics Program. He received his medical degree from Indiana University and completed Residency and Fellowship at Riley Hospital for Children, while also obtaining his master’s degree in Clinical Investigation. His research is currently focused on finding new agents for the treatment of relapsed sarcomas (specifically rhabdomyosarcoma, osteosarcoma, and Ewings sarcoma).

Key Publications

 

Därr R, Nambuba J, Del Rivero J, Janssen I, Merino M, Todorovic M, Balint B, Jochmanova I, Prchal JT, Lechan RM, Tischler AS, Popovic V, Miljic D, Adams KT, Prall FR, Ling A, Golomb MR, Ferguson M, Nilubol N, Chen CC, Chew E, Taïeb D, Stratakis CA, Fojo T, Yang C, Kebebew E, Zhuang Z, Pacak K. Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. Endocr Relat Cancer. 2016 Dec;23(12):899-908. Epub 2016 Sep 27.

 

Hanemann CO, Blakeley JO, Nunes FP, Robertson K, Stemmer-Rachamimov A, Mautner V, Kurtz A, Ferguson M, Widemann BC, Evans DG, Ferner R, Carroll SL, Korf B, Wolkenstein P, Knight P, Plotkin SR; REiNS International Collaboration. Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology. 2016 Aug 16;87(7 Suppl 1):S40-8

 

Ferguson MJ, Rhodes, SJ, Jiang L, Li X, Yuan J, Yang X, Zhang S, Vakili ST, Territo P, Hutchins GD, Yang FC, Clapp DW, Chen S. Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas. Pediatric Blood Cancer. 2016 Feb;63(2):206-13.

 

Ferguson MJ, Hingorani P, Gupta AA. Emerging Molecular-Targeted Therapies in Early-Phase Clinical Trials and Preclinical Models. What’s New and Improved in the Care of Children with Rhabdomyosarcoma? ASCO 2013. Educational Book 420-424

 

Egbelakin A, Ferguson MJ, Macgill EA, Lehmann AS, Topletz AR, Quinney SK, Li L, McCammack KC, Hall SD, Renbarger JL. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011 Mar;56(3): 361-7

 

Kevin M. Sheridan, Michael J. Ferguson, Matthew R. Distasi, Frank A. Witzmann, Michael C. Dalsing, Steven J Miller, Joseph L. Unthank. Impact of genetic background and aging on mesenteric collateral growth capacity in Fischer 344, Brown Norway, and Fischer 344-Brown Norway hybrid rats. American Journal of Physiology-Heart and Circulatory Physiology. 2007 Dec; 293(3): H3498-3505.

 

McKee EE, Ferguson M, Bentley AT, Marks, TA. Inhibition of Mammalian Mitochondrial Protein Synthesis by Oxazolidinones. Antimicrobial Agents and Chemotherapy 50: June 2006

 

Titles & Appointments

  • Assistant Professor of Clinical Pediatrics
  • Education
    2015 MS Indiana University School of Medicine
    2015 MS Indiana University
    2015 MS Indiana University
    2014 FEL Indiana University School of Medicine
    2014 FEL Indiana University School of Medicine
    2013 FEL Indiana University School of Medicine
    2013 FEL Indiana University School of Medicine
    2010 RES Indiana University School of Medicine
    2010 RES Indiana University School of Medicine
    2007 MD Indiana University School of Medicine
    2007 MD Indiana University
    2007 MD Indiana University
    2004 MS Indiana University Purdue University-Indianapolis
    2004 MS Indiana University
    2004 MS Indiana University
    1999 BS University of Notre Dame
    1999 BS University of Notre Dame
    1999 BS University of Notre Dame
  • Research

     

    Research is focused on identifying novel agents for the treatment of relapsed sarcomas (specifically rhabdomyosarcoma, osteosarcoma, and Ewings sarcoma) based on results of precision genomics testing utilizing deep sequencing, transcriptome, proteome, and IHC data in patients.  In parallel with the clinical component of this project, laboratory based evaluation of patient-derived cell lines, and preclinical xenograft models developed from this same population of patients will allow broader evaluation of potential therapeutic options as well as discovery of novel targets via a comprehensive ‘omic’ investigation.

     

  • Professional Organizations
    American Society of Pediatric Hematology/Oncology
  • Board Certifications
    American Board of Pediatrics - Pediatric Hematology-Oncology
    American Board of Pediatrics - Pediatrics
  • Clinical Interests

    Pediatric Cancer Precision Genomics, Sarcomas.

Looking for patient care?

To schedule an appointment with a faculty member physician of IU School of Medicine, contact Indiana University Health at 888-484-3258 or use the physician finder by clicking the button below.

Find a doctor